natgillin/translations-raw huggingface dataset:
ZYPREXA VELOTAB orodispersible tablet should be placed in the mouth, where it will rapidly disperse in saliva, so it can be easily swallowed. 
ZYPREXA VELOTAB orodisperzibilno tableto naj se položi v usta, kjer se hitro dispergira v slini,
ZYPREXA VELOTAB contains sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate, which may cause an allergic reaction in some people. 
Zdravilo ZYPREXA VELOTAB vsebuje natrijev metilparahidroksibenzoat in natrijev propilparahidroksibenzoat, ki lahko pri nekaterih ljudeh povzročita alergijsko reakcijo.
Patients who cannot take phenylalanine should note that ZYPREXA VELOTAB contains aspartame, which is a source of phenylalanine. 
Bolniki, ki ne smejo zaužiti fenilalanina, naj se zavedajo, da zdravilo ZYPREXA VELOTAB vsebuje aspartam, ki je vir fenilalanina.
Patients who cannot take mannitol should note that ZYPREXA VELOTAB contains mannitol. 
Bolniki, ki ne smejo prejeti manitola, naj se zavedajo, da zdravilo ZYPREXA VELOTAB vsebuje manitol.
Hold the blister strip at the edges and separate one blister cell from the rest of the strip by gently tearing along the perforations around it. 
Primite pretisni omot na robovih in ločite en pretisni razdelek od ostalih razdelkov omota tako,
Consult your doctor if your symptoms return but do not stop taking ZYPREXA VELOTAB unless your doctor tells you to. 
Če se simptomi povrnejo, se posvetujte s svojim zdravnikom, vendar ne prenehajte jemati zdravila ZYPREXA
ZYPREXA VELOTAB orodispersible tablets are for oral use. 
ZYPREXA VELOTAB tablete so za peroralno uporabo.
Systemic Symptoms (DRESS) 
Reakcija na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS)
What ZYPREXA VELOTAB looks like and contents of the pack ZYPREXA VELOTAB 5 mg, 10 mg, 15 mg and 20 mg are yellow orodispersible tablets. 
Izgled zdravila ZYPREXA VELOTAB in vsebina pakiranja ZYPREXA VELOTAB 5 mg, 10 mg, 15 mg in 20 mg so rumene orodisperzibilne tablete.
Mannitol ZYPREXA VELOTAB orodispersible tablet contains mannitol. 
Manitol ZYPREXA VELOTAB orodisperzibilna tableta vsebuje manitol.
ZYPREXA VELOTAB with alcohol 
Jemanje zdravila ZYPREXA VELOTAB skupaj z alkoholom
Transient, asymptomatic elevations of hepatic aminotransferases, ALT, AST have been seen commonly, especially in early treatment. 
Jetrno delovanje Pogosto so opažali prehodna, asimptomatska zvišanja jetrnih aminotransferaz, ALT in AST, posebno na začetku zdravljenja.
An updated RMP should be submitted: • At the request of the European Medicines Agency 
Posodobljen RMP je treba predložiti:
If you suddenly stop taking ZYPREXA VELOTAB, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur. 
Če nenadno prenehate jemati zdravilo ZYPREXA VELOTAB, se lahko pojavijo simptomi, kot so znojenje, nespečnost, tresenje, občutek tesnobe ali slabost in bruhanje.
ZYPREXA VELOTAB orodispersible tablet contains aspartame, which is a source of phenylalanine. 
ZYPREXA VELOTAB orodisperzibilna tableta vsebuje aspartam, ki je vir fenilalanina.
However, the incidence of death was higher in olanzapine-treated than in placebotreated patients independent of these risk factors. 
Vendar je bila incidenca smrti, neodvisno od omenjenih dejavnikov tveganja, večja pri bolnikih zdravljenih z olanzapinom, kot pri bolnikih zdravljenih s placebom.
In placebo-controlled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5% vs. 1.5 %, respectively). 
povezano z demenco in/ali vedenjskimi motnjami (povprečna starost 78 let), je bilo 2-kratno povečanje incidence smrti pri bolnikih, zdravljenih z olanzapinom, v primerjavi z bolniki, zdravljenimi s placebom (3,5 % v primerjavi z 1,5 %).
Excipients with known effect: Each orodispersible tablet contains 0.60 mg aspartame, 
Pomožne snovi z znanim učinkom: Ena orodisperzibilna tableta vsebuje 0,60 mg aspartama
In an 18-month co-therapy study in manic or mixed episode patients stabilised with olanzapine plus a mood stabiliser (lithium or valproate), long-term olanzapine co-therapy with lithium or valproate was not statistically significantly superior to lithium or valproate alone in delaying bipolar recurrence, defined according to syndromic (diagnostic) criteria. 
V 18-mesečni študiji sočasnega zdravljenja pri bolnikih z manično ali mešano epizodo, stabiliziranih z olanzapinom skupaj s stabilizatorjem razpoloženja (litij ali valproat), dolgotrajno sočasno zdravljenje z olanzapinom skupaj z litijem ali valproatom ni bilo statistično značilno bolj ugodno kot zdravljenje samo z litijem ali samo valproatom pri odlogu ponovnega pojava bipolarne motnje,
Separate one blister cell from the strip. 
Ločite en pretisni razdelek od ostalih razdelkov pretisnega omota.
Other symptoms may be: acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness, slowing of the breathing rate, aspiration, high blood pressure or low blood pressure, abnormal rhythms of the heart. 
krči (epilepsija), koma, kombinacija zvišane telesne temperature, hitrega dihanja, znojenja, okorelosti mišic in omotičnosti ali zaspanosti, upočasnjeno dihanje, aspiracija, visok krvni tlak ali nizek krvni tlak, motnje srčnega ritma.
Do not drink any alcohol if you have been given ZYPREXA VELOTAB as together with alcohol it may make you feel drowsy. 
Če ste dobili zdravilo ZYPREXA VELOTAB, ne pijte nobenega alkohola, saj lahko zdravilo ZYPREXA VELOTAB in alkohol skupaj povzročita občutek zaspanosti.
If you take more ZYPREXA VELOTAB than you should Patients who have taken more ZYPREXA VELOTAB than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, 
Če ste vzeli večji odmerek zdravila ZYPREXA VELOTAB, kot bi smeli Bolniki, ki so vzeli večji odmerek zdravila ZYPREXA VELOTAB, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
Olanzapine demonstrated a greater in vitro affinity for serotonin 5HT2 than dopamine D2 receptors and greater 5 HT2 than D2 activity in vivo models. 
5-HT2 kot za dopaminske D2 receptorje in večjo 5-HT2 kot D2 aktivnost v modelih in vivo.
How to take ZYPREXA VELOTAB 
Kako jemati zdravilo ZYPREXA VELOTAB
MARKETING AUTHORISATION NUMBER (S) 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET Z ZDRAVILOM
ANNEX II A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE GLEDE DOVOLJENJA ZA
Other ingredients: gelatin, mannitol (E421), aspartame (E951), sodium methyl parahydroxybenzoate (E219), sodium propyl parahydroxybenzoate (E217). 
Pomožne snovi: želatina, manitol (E421), aspartam (E951), natrijev metilparahidroksibenzoat (E219), natrijev propilparahidroksibenzoat (E217).
Following short term treatment (median duration 47 days), weight gain ≥ 7% of baseline body weight was very common (22.2 %), ≥ 15 % was common (4.2 %) and ≥ 25 % was uncommon (0.8 %). 
S kratkoročnim zdravljenjem (srednje trajanje 47 dni) povezano zvečanje telesne mase za ≥ 7 % od osnovne telesne mase je bilo zelo pogosto (22,2 %), ≥ 15 %
In renally impaired patients (creatinine clearance < 10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus 25.0 l/hr). 
Okvarjeno delovanje ledvic Pri bolnikih z okvarjenim delovanjem ledvic (očistek kreatinina < 10 ml/min) v primerjavi z zdravimi osebami ni bilo značilne razlike v srednjem razpolovnem času izločanja (37,7 v primerjavi z 32,4 ure)
ZYPREXA VELOTAB contains aspartame, mannitol and sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate 
Zdravilo ZYPREXA VELOTAB vsebuje aspartam, manitol, natrijev metilparahidroksibenzoat in natrijev propilparahidroksibenzoat
If you stop taking ZYPREXA VELOTAB 
Če ste pozabili vzeti zdravilo ZYPREXA VELOTAB
There is a risk of feeling drowsy when you are given ZYPREXA VELOTAB. 
Obstaja tveganje, da se boste po tem, ko ste dobili zdravilo ZYPREXA VELOTAB, počutili zaspane.
Sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate Olanzapine orodispersible tablet contains sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate. 
Natrijev metilparahidroksibenzoat in natrijev propilparahidroksibenzoat Orodisperzibilna tableta olanzapina vsebuje natrijev metilparahidroksibenzoat in natrijev propilparahidroksibenzoat.
The most frequently (seen in ≥ 1% of patients ) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema. 
ortostatska hipotenzija, antiholinergični učinki, prehodna asimptomatska zvišanja jetrnih aminotransferaz (glejte poglavje 4.4), izpuščaj, astenija, utrujenost, pireksija, artralgija, zvišana alkalna fosfataza, visoka raven gama-glutamiltransferaze, visoka raven sečne kisline, visoka raven kreatin-fosfokinaze in edem.
• The other ingredients are - gelatin, mannitol (E421), aspartame (E951), sodium methyl parahydroxybenzoate (E219) and sodium propyl parahydroxybenzoate (E217). 
- Pomožne snovi so želatina, manitol (E421), aspartam (E951), natrijev metilparahidroksibenzoat (E219) in natrijev propilparahidroksibenzoat (E217).
Other medically significant sequelae of overdose include delirium, convulsion, coma, possible neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension, cardiac arrhythmias (< 2 % of overdose cases) and cardiopulmonary arrest. 
komo, možen nevroleptični maligni sindrom, depresijo dihanja, aspiracijo, hipertenzijo ali hipotenzijo, motnje srčnega ritma (< 2 % primerov prevelikega odmerjanja) in kardiopulmonalni zastoj.
Patients gaining ≥ 7 %, ≥ 15 % and ≥ 25 % of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively). 
Zvečanje osnovne telesne mase za ≥ 7 %, ≥ 15 % in ≥ 25 % se je pri dolgoročni izpostavljenosti bolnikov (vsaj 48 tednov) pojavljalo zelo pogosto (v
Reversible neutropenia, thrombocytopenia, or anaemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [area under the curve] is 12- to 15-fold greater than that of a man given a 12-mg dose). 
Pri nekaj psih, ki so prejemali 8 ali 10 mg/kg/dan (celotno izpostavljanje olanzapinu [površina pod krivuljo] je 12do 15-krat večje kot pri človeku, ki dobi 12-miligramski odmerek), se je razvila reverzibilna nevtropenija, trombocitopenija ali anemija.
ZYPREXA VELOTAB 5 mg orodispersible tablets ZYPREXA VELOTAB 10 mg orodispersible tablets ZYPREXA VELOTAB 15 mg orodispersible tablets ZYPREXA VELOTAB 20 mg orodispersible tablets 
ZYPREXA VELOTAB 5 mg orodisperzibilne tablete ZYPREXA VELOTAB 10 mg orodisperzibilne tablete ZYPREXA VELOTAB 15 mg orodisperzibilne tablete ZYPREXA VELOTAB 20 mg orodisperzibilne tablete olanzapin
Only take other medicines while you are on ZYPREXA VELOTAB if your doctor tells you that you can. You might feel drowsy if ZYPREXA VELOTAB is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers). 
Če jemljete zdravilo ZYPREXA VELOTAB v kombinaciji z zdravili za zdravljenje depresije, zdravili za zdravljenje občutkov tesnobe ali zdravili, ki vam pomagajo spati (pomirjevala), se lahko počutite zaspani.
Patients treated with any antipsychotic medicines, including ZYPREXA VELOTAB, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines, e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter. 
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom ZYPREXA VELOTAB, moramo redno spremljati glede lipidov, v skladu z znanimi priporočili za antipsihotike,
• High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking ZYPREXA VELOTAB. 
• Pri bolnikih, ki so jemali zdravilo ZYPREXA VELOTAB, so opazili visok nivo sladkorja v krvi in visok nivo maščob (trigliceridov in holesterola).
What you need to know before you take ZYPREXA VELOTAB 3. 
Kaj morate vedeti, preden boste vzeli zdravilo ZYPREXA VELOTAB Ne jemljite zdravila ZYPREXA VELOTAB:
13 Following short term treatment (median duration 22 days), weight gain ≥ 7% of baseline body weight (kg) was very common (40.6 %), ≥ 15% of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %). 
od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), za ≥ 15 % pogosto (7,1 %) in za ≥ 25 %
Common side effects (may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes ; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements (dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever, joint pain and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males. 
Pogosti neželeni učinki (lahko prizadenejo do 1 od 10 bolnikov) vključujejo spremembe v ravneh nekaterih krvnih celic in maščob v krvnem obtoku in v začetnih obdobjih zdravljenja, začasno povišanje jetrnih encimov, zvišanja v ravni sladkorjev v krvi in urinu, zvišanja v ravni sečne kisline in kreatin fosfokinaze v krvi, večji občutek lakote, omotico, nemirnost, tresenje, nenavadne gibe
Thromboembolism hypotension10 
Žilne bolezni Ortostatska hipotenzija10
Potential interactions affecting olanzapine 
Zmožnost vplivanja olanzapina na druga zdravila
INFORMATION IN BRAILLE ZYPREXA VELOTAB 20 mg 
PODATKI V BRAILLOVI PISAVI ZYPREXA VELOTAB 20 mg
• Weight gain has been seen in patients taking ZYPREXA VELOTAB. 
• Pri bolnikih, ki so jemali zdravilo ZYPREXA VELOTAB, so opazili porast telesne mase.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely ( ≥ 0.01 % and < 0.1 %) when olanzapine is stopped abruptly. 
Prekinitev zdravljenja Redko (≥ 0,01 % in < 0,1 %) so pri nenadni prekinitvi zdravljenja z olanzapinom poročali o akutnih simptomih, kot so znojenje, nespečnost, tresenje, občutek tesnobe, slabost ali bruhanje.
Each ZYPREXA VELOTAB orodispersible tablet contains either 5 mg, 10 mg, 15 mg or 20 mg of the active substance. 
5 mg, 10 mg, 15 mg ali 20 mg učinkovine.
Reproductive system and breast disorders Erectile dysfunction in males 
Erektilna disfunkcija pri moških
0.30 mg sodium methyl parahydroxybenzoate, 0.10 mg sodium propyl parahydroxybenzoate. 
0,30 mg natrijevega metilparahidroksibenzoata 0,10 mg natrijevega propilparahidroksibenzoata
Changes in fasting triglycerides from borderline at baseline (≥ 1.69 mmol/l 
Zelo pogoste so bile spremembe v ravneh celokupnega holesterola na tešče z mejnih osnovnih vrednosti (≥ 4,39 mmol/l
INFORMATION IN BRAILLE ZYPREXA VELOTAB 5 mg 
PODATKI V BRAILLOVI PISAVI ZYPREXA VELOTAB 5 mg
Dystonia (including oculogyration) 11 
(vključno z okulogiracijo) 11 Tardivne diskinezije11
INFORMATION IN BRAILLE ZYPREXA VELOTAB 10 mg 
PODATKI V BRAILLOVI PISAVI ZYPREXA VELOTAB 10 mg
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer responsible for batch release Lilly S.A., Avda. 
Ime in naslov izdelovalcev, odgovornih za sproščanje serije
INFORMATION IN BRAILLE ZYPREXA VELOTAB 15 mg 
PODATKI V BRAILLOVI PISAVI ZYPREXA VELOTAB 15 mg
0.225 mg sodium methyl parahydroxybenzoate, 0.075 mg sodium propyl parahydroxybenzoate. 
0,225 mg natrijevega metilparahidroksibenzoata 0,075 mg natrijevega propilparahidroksibenzoata ZYPREXA VELOTAB 20 mg orodisperzibilne tablete Ena orodisperzibilna tableta vsebuje 20 mg olanzapina.
ZYPREXA VELOTAB 20 mg orodispersible tablets 
ZYPREXA VELOTAB 20 mg orodisperzibilne tablete olanzapin
Sodium methyl parahydroxybenzoate (E219) Sodium propyl parahydroxybenzoate (E217) 
6.1 Seznam pomožnih snovi želatina manitol (E421) aspartam (E951) natrijev metilparahidroksibenzoat (E219) natrijev propilparahidroksibenzoat (E217)
ZYPREXA VELOTAB 5 mg orodispersible tablets 
ZYPREXA VELOTAB 5 mg orodisperzibilne tablete olanzapin
0.1125 mg sodium methyl parahydroxybenzoate, 0.0375 mg sodium propyl parahydroxybenzoate. 
0,1125 mg natrijevega metilparahidroksibenzoata 0,0375 mg natrijevega propilparahidroksibenzoata ZYPREXA VELOTAB 10 mg orodisperzibilne tablete Ena orodisperzibilna tableta vsebuje 10 mg olanzapina.
ZYPREXA VELOTAB 10 mg orodispersible tablets 
ZYPREXA VELOTAB 10 mg orodisperzibilne tablete olanzapin
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON OF ZYPREXA VELOTAB 20 mg ORODISPERSIBLE TABLETS 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA Z ZYPREXA VELOTAB 20 mg ORODISPERZIBILNIMI TABLETAMI
ZYPREXA VELOTAB 15 mg orodispersible tablets 
ZYPREXA VELOTAB 15 mg orodisperzibilne tablete olanzapin
Uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling in the mouth and throat, itching, rash); diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma; seizures, usually associated with a history of seizures (epilepsy); muscle stiffness or spasms ( including eye movements); restless legs syndrome; problems with speech; stuttering; slow heart rate; sensitivity to sunlight; bleeding from the nose; abdominal distension; memory loss or forgetfulness; urinary incontinence; lack of ability to urinate; hair loss; absence or decrease in menstrual periods; and changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth. 
občasno povezano s ketoacidozo (ketoni v krvi in urinu) ali komo, krče, običajno povezane s krči (epileptičnimi napadi) v preteklosti, mišično okorelost ali krče (vključno z obračanjem zrkel), sindrom nemirnih nog, težave pri govoru, jecljanje, upočasnjen srčni utrip, občutljivost za sončno svetlobo,
0.15 mg sodium methyl parahydroxybenzoate, 0.05 mg sodium propyl parahydroxybenzoate. 
0,15 mg natrijevega metilparahidroksibenzoata 0,05 mg natrijevega propilparahidroksibenzoata ZYPREXA VELOTAB 15 mg orodisperzibilne tablete Ena orodisperzibilna tableta vsebuje 15 mg olanzapina.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON OF ZYPREXA VELOTAB 10 mg ORODISPERSIBLE TABLETS 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA Z ZYPREXA VELOTAB 10 mg ORODISPERZIBILNIMI TABLETAMI
Neutropenia 
Zaspanost
Changes in total fasting cholesterol levels from borderline at baseline (≥ 4.39 - < 5.17 mmol/l) to high (≥ 5.17 mmol/l) were very common. 
Zelo pogoste so bile spremembe v ravneh celokupnega holesterola na tešče z mejnih osnovnih vrednosti (≥ 5,17 mmol/l - < 6,2 mmol/l) na visoke (≥ 6,2 mmol/l).
EU/1/99/125/001 28 orodispersible tablets EU/1/99/125/009 35 orodispersible tablets EU/1/99/125/005 56 orodispersible tablets EU/1/99/125/013 70 orodispersible tablets EU/1/99/125/017 98 orodispersible tablets 
EU/1/99/125/001 28 orodispersibilnih tablet EU/1/99/125/009 35 orodispersibilnih tablet EU/1/99/125/005 56 orodispersibilnih tablet EU/1/99/125/013 70 orodispersibilnih tablet EU/1/99/125/017 98 orodispersibilnih tablet
EU/1/99/125/003 28 orodispersible tablets EU/1/99/125/011 35 orodispersible tablets EU/1/99/125/007 56 orodispersible tablets EU/1/99/125/015 70 orodispersible tablets EU/1/99/125/019 98 orodispersible tablets 
EU/1/99/125/003 28 orodispersibilnih tablet EU/1/99/125/011 35 orodispersibilnih tablet EU/1/99/125/007 56 orodispersibilnih tablet EU/1/99/125/015 70 orodispersibilnih tablet EU/1/99/125/019 98 orodispersibilnih tablet
EU/1/99/125/004 28 orodispersible tablets EU/1/99/125/012 35 orodispersible tablets EU/1/99/125/008 56 orodispersible tablets EU/1/99/125/016 70 orodispersible tablets EU/1/99/125/020 98 orodispersible tablets 
EU/1/99/125/004 28 orodispersibilnih tablet EU/1/99/125/012 35 orodispersibilnih tablet EU/1/99/125/008 56 orodispersibilnih tablet EU/1/99/125/016 70 orodispersibilnih tablet EU/1/99/125/020 98 orodispersibilnih tablet
EU/1/99/125/002 28 orodispersible tablets EU/1/99/125/010 35 orodispersible tablets EU/1/99/125/006 56 orodispersible tablets EU/1/99/125/014 70 orodispersible tablets EU/1/99/125/018 98 orodispersible tablets 
EU/1/99/125/002 28 orodispersibilnih tablet EU/1/99/125/010 35 orodispersibilnih tablet EU/1/99/125/006 56 orodispersibilnih tablet EU/1/99/125/014 70 orodispersibilnih tablet EU/1/99/125/018 98 orodispersibilnih tablet
• The active substance is olanzapine. 
Začetni odmerek olanzapina je bil
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON OF ZYPREXA VELOTAB 5 mg ORODISPERSIBLE TABLETS 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA Z ZYPREXA VELOTAB 5 mg ORODISPERZIBILNIMI TABLETAMI
< 2.26 mmol/l) to high (≥ 2.26 mmol/l) were very common. 
< 5,17 mmol/l) na visoke (≥ 5,17 mmol/l).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON OF ZYPREXA VELOTAB 15 mg ORODISPERSIBLE TABLETS 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA Z ZYPREXA VELOTAB 15 mg ORODISPERZIBILNIMI TABLETAMI
Talk to your doctor or pharmacist before you take ZYPREXA VELOTAB 
Pred začetkom jemanja zdravila ZYPREXA VELOTAB se posvetujte s svojim zdravnikom ali s farmacevtom.
ZYPREXA VELOTAB contains the active substance olanzapine. 
Kaj vsebuje zdravilo ZYPREXA VELOTAB - Učinkovina je olanzapin.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS ZYPREXA VELOTAB 20 mg ORODISPERSIBLE TABLETS: BLISTER FOIL LABEL 
ZYPREXA VELOTAB 20 mg ORODISPERZIBILNE TABLETE: OZNAKA FOLIJE PRETISNEGA OMOTA
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS ZYPREXA VELOTAB 15 mg ORODISPERSIBLE TABLETS: BLISTER FOIL LABEL 
ZYPREXA VELOTAB 15 mg ORODISPERZIBILNE TABLETE: OZNAKA FOLIJE PRETISNEGA OMOTA
What ZYPREXA VELOTAB is and what it is used for 2. 
Kaj je zdravilo ZYPREXA VELOTAB in za kaj ga uporabljamo Zdravilo ZYPREXA VELOTAB vsebuje zdravilno učinkovino olanzapin.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS ZYPREXA VELOTAB 5 mg ORODISPERSIBLE TABLETS: BLISTER FOIL LABEL 
ZYPREXA VELOTAB 5 mg ORODISPERZIBILNE TABLETE: OZNAKA FOLIJE PRETISNEGA OMOTA
(≥ 2.26 mmol/l). 
(≥ 5,56 mmol/l - < 7 mmol/l) na visoke (≥ 7 mmol/l).
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS ZYPREXA VELOTAB 10 mg ORODISPERSIBLE TABLETS: BLISTER FOIL LABEL 
ZYPREXA VELOTAB 10 mg ORODISPERZIBILNE TABLETE: OZNAKA FOLIJE PRETISNEGA OMOTA
Changes in fasting glucose from borderline at baseline (≥ 5.56 - < 7 mmol/l) to high (≥ 7 mmol/l) 
Zelo pogoste so bile spremembe v ravneh trigliceridov na tešče z mejnih osnovnih vrednosti (≥ 1,69 mmol/l - < 2,26 mmol/l) na visoke (≥ 2,26 mmol/l).
This summary was last updated in June 2015. 
Povzetek je bil nazadnje posodobljen junija 2015.
UpCard is available as tablets (0.75 mg, 3 mg, 7.5 mg and 18 mg) and can only be obtained with a prescription. 
Zdravilo UpCard je na voljo v obliki tablet (0,75 mg, 3 mg, 7,5 mg in 18 mg) in se izdaja le na recept.
The full EPAR for UpCard can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila UpCard je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.